Investigating Lipid Accumulation in the Right Ventricle of Patients with Pulmonary Arterial Hypertension
Official title: Clinical and Mechanistic Understanding of Right Ventricular Steatosis in Pulmonary Arterial Hypertension (PAH)
Run by Vanderbilt University Medical Center · NCT05462574 · Data updated 2026-11-12
This study is trying to see how fat buildup in the right side of the heart affects the health and exercise ability of people with pulmonary arterial hypertension.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 75 (estimated) |
| Sponsor | Vanderbilt University Medical Center Academic / other |
| Locations | 1 site (Nashville, Tennessee) |
| Status | Recruiting |
| Started | January 17, 2023 |
| Main results expected | September 30, 2027 |
| Study ends | September 30, 2027 |
| Registry record updated | May 29, 2026 |
| Trial ID | NCT05462574 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older diagnosed with idiopathic, heritable, or connective tissue disease-associated PAH who are stable on their medication regimen.
✕Probably not a fit
Patients with functional class IV heart failure or those unable to undergo necessary testing such as MRI/MRS may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the relationship between right ventricle (RV) lipid accumulation and RV function, exercise capacity, and clinical outcomes in patients with pulmonary arterial hypertension (PAH). The study will measure lipid levels in the RV and left ventricle, assess exercise capacity through tests like the 6-minute walk test, and analyze potential drivers of lipid accumulation, including BMPR2 expression and lipid metabolism. Participants will be followed over time to understand the natural history of RV steatosis and its impact on health.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of pulmonary arterial hypertension, potentially enhancing patient outcomes.
How similar studies have gone: While the specific focus on RV lipid accumulation in PAH is novel, related studies have shown promising results in understanding lipid metabolism in cardiovascular diseases.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: * ≥ 18 years old * Diagnosed with idiopathic, heritable, connective tissue disease-associated PAH, associated pulmonary arterial hypertension (PAH), or drug-or toxin-associated PAH according to World Health Organization (WHO) consensus recommendations. * Stable PAH-specific medication regimen for three months prior to enrollment. Adjustments in IV prostacyclin for side effect management are allowed. Diuretic adjustments are permitted. * WHO Functional Class I-III * Ambulatory * Able to have an MRI/MRS, perform a 6MWD test, and cardiopulmonary exercise test Exclusion criteria: * Pregnancy * Diagnosis of PAH etiology other than idiopathic, heritable, connective tissue disease - associated PAH or associated with drugs and toxins * WHO Functional class IV heart failure * Requirement for continuous oxygen * Unable to have an MRI/MRS, perform a 6MWD test, or cardiopulmonary exercise test. * Patients with implanted/embedded ferromagnetic material that would preclude cardiac MRI
Where it's running
-
Vanderbilt University Medical Center
Nashville, Tennessee, United States Recruiting
Study contacts
- Principal investigator: Evan Brittain, MD, MSCI — Vanderbilt University Medical Center
- Study coordinator: Natasha Billard
- Email: natasha.billard.1@vumc.org
- Phone: (434) 851-3306
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding risk and resilience in pulmonary arterial hypertension
This study is trying to understand why some people with certain genetic changes get pulmonary arterial hypertension while others don’t, by looking at different markers in their bodies over time.
-
Understanding hormonal and metabolic factors in pulmonary arterial hypertension
This study is trying to see how hormones like estrogen and testosterone, along with metabolic factors, affect pulmonary arterial hypertension (PAH) differently in men and women to help improve treatment options.
-
Rutgers Genetics of Pulmonary Hypertension
This online project will try to see if genetic differences affect the risk of pulmonary hypertension in U.S. adults, and anyone 18 or older can join whether or not they have PH.
-
Takayasu arteritis that affects the lung arteries: symptoms and long-term outlook
This project will follow people with Takayasu arteritis involving the pulmonary arteries to see what their symptoms, treatments, and long-term outcomes are.
-
Using 129Xe MRI to Diagnose and Monitor Pulmonary Arterial Hypertension
This study is testing if a special type of MRI can help doctors spot different types of Pulmonary Arterial Hypertension and track how the disease changes over time in people with this condition.
-
Understanding how low-load leg exercises affect muscle and blood flow in PAH patients
This substudy tests whether a gentle leg exercise program can change blood flow and oxygen use in the calf muscles of adults with pulmonary arterial hypertension.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.